Coenzyme Q10 supplementation lowers hepatic oxidative stress and inflammation associated with diet-induced obesity in mice


To cite this version:
Accepted Manuscript

Title: Coenzyme Q10 supplementation lowers hepatic oxidative stress and inflammation associated with diet-induced obesity in mice

Authors: Florence M. Sohet, Audrey M. Neyrinck, Barbara D. Pachikian, Fabienne C. de Backer, Laure B. Bindels, Petra Niklowitz, Thomas Menke, Patrice D. Cani, Nathalie M. Delzenne

PII: S0006-2952(09)00638-8
DOI: doi:10.1016/j.bcp.2009.07.008
Reference: BCP 10264

To appear in: BCP

Received date: 12-6-2009
Revised date: 15-7-2009
Accepted date: 15-7-2009

Please cite this article as: Sohet FM, Neyrinck AM, Pachikian BD, de Backer FC, Bindels LB, Niklowitz P, Menke T, Cani PD, Delzenne NM, Coenzyme Q10 supplementation lowers hepatic oxidative stress and inflammation associated with diet-induced obesity in mice, Biochemical Pharmacology (2008), doi:10.1016/j.bcp.2009.07.008

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Coenzyme Q10 supplementation lowers hepatic oxidative stress and inflammation associated with diet-induced obesity in mice

Florence M. SOHET\textsuperscript{a}, Audrey M. NEYRINCK\textsuperscript{a}, Barbara D. PACHIKIAN\textsuperscript{a}, Fabienne C. DE BACKER\textsuperscript{a}, Laure B. BINDELS\textsuperscript{a}, Petra NIKLOWITZ\textsuperscript{b}, Thomas MENKE\textsuperscript{b}, Patrice D. CANI\textsuperscript{a} and Nathalie M. DELZENNE\textsuperscript{a}

\textsuperscript{a} Louvain Drug Research Institute, Nutrition and metabolism research group, Université catholique de Louvain, Brussels, Belgium
\textsuperscript{b} Children’s Hospital of Datteln, University of Witten/Herdecke, Datteln, Germany

E-mail address of each author: Florence M. SOHET : florence.sohet@uclouvain.be; Audrey M. NEYRINCK: audrey.neyrinck@uclouvain.be; Barbara D. PACHIKIAN: barbara.pachikian@uclouvain.be; Fabienne C. DE BACKER: fabienne.debacker@uclouvain.be; Laure B. BINDELS: laure.bindels@uclouvain.be; Petra NIKLOWITZ: pf-niklowitz@web.de; Thomas MENKE : t.menke@kinderklinikdatteln.de ; Patrice D. CANI : patrice.cani@uclouvain.be; Nathalie M. DELZENNE : nathalie.delzenne@uclouvain.be

Corresponding author: Nathalie M. Delzenne
Louvain Drug Research Institute,
Nutrition and metabolism research group, Université catholique de Louvain,
Unit PMNT, Av. E. Mounier, 73/69, 1200 Brussels, Belgium
Fax: +32 02 764 73 59  Tel: +32 02 764 73 67
email: nathalie.delzenne@uclouvain.be

Running title: High-fat, fructose and coenzyme Q10 in obesity

Keywords: high-fat feeding; fructose; coenzyme Q10; oxidative stress; inflammation

Classification: Metabolic Disorders and Endocrinology
Abstract

Background: Diabetes and obesity are metabolic disorders induced by an excessive dietary intake of fat, usually related to inflammation and oxidative stress.

Aims: The aim of the study is to investigate the effect of the antioxidant coenzyme Q10 (CoQ10) on hepatic metabolic and inflammatory disorders associated with diet-induced obesity and glucose intolerance.

Methods: C57bl6/j mice were fed for 8 weeks, either a control diet (CT) or a high fat diet plus 21% fructose in the drinking water (HFF). CoQ10 supplementation was performed in this later condition (HFFQ).

Results: HFF mice exhibit increased energy consumption, fat mass development, fasting glycemia and insulinemia and impaired glucose tolerance. HFF treatment promoted the expression of genes involved in reactive oxygen species production (NADPH oxidase), inflammation (CRP, STAMP-2) and metabolism (CPT1α) in the liver. CoQ10 supplementation decreased the global hepatic mRNA expression of inflammatory and metabolic stresses markers without changing obesity and tissue lipid peroxides compared to HFF mice. HFF diets paradoxically decreased TBARS (reflecting lipid peroxides) levels in liver, muscle and adipose tissue versus CT group, an effect related to vitamin E content of the diet.

Conclusion: In conclusion, HFF model promotes glucose intolerance and obesity by a mechanism independent on the level of tissue peroxides. CoQ10 tends to decrease hepatic stress gene expression, independently of any modulation of lipid peroxidation, which is classically considered as its most relevant effect.
1. Introduction

The incidence of obesity and type 2 diabetes is increasing all over the world. Oxidative and inflammatory stresses are both considered as important events that participate to the development of metabolic disorders associated with insulin resistance and obesity [1-6]. It has been shown that a high fat (HF) diet promotes endotoxemia and thereby increases proinflammatory cytokines production, namely in the liver [7,8]. Upon obesity, proinflammatory cytokines and oxidative stress have been shown to drive metabolic disturbances, such as insulin resistance and activation of immune system in the liver, in the adipose tissue and in the muscle [5,6,9]. Under different pathological states such as diabetes, obesity and hypertriglyceridemia, many tissues are subject to increased reactive oxygen species level, mostly produced through the NADPH oxidase pathway. In the liver, NADPH oxidases enzymes may be involved in several mechanisms leading to insulin resistance and inflammation such as of the activation of c-jun N-terminal kinase, JNK, pathway and interaction with tumour necrosis factor-α (TNFα)[10].

Among carbohydrates, fructose has been described as a nutrient able to promote insulin resistance and oxidative stress [11]. Those metabolic disturbances have been associated with i.e. hypertriglyceridemia and steatosis, linked to an increased de novo lipogenesis [12,13], modification of the activity of enzymes involved in hepatic glucose metabolism and glucose uptake pathways [14,15] and activation of NADPH oxidase pathway [11]. Coenzyme Q10 (CoQ10) appears as an interesting component, susceptible to counteract several metabolic disturbances associated with obesity. When injected in animals, CoQ10 modulates blood lipid profiles and decreases adipose tissue mRNA expression of the pro-inflammatory cytokine TNFα in ob/ob mice, blunts the rosiglitazone increased fat mass in
ob/ob and diet-induced obesity mice and enhances the rosiglitazone effect on glucose tolerance of ob/ob mice [16]. It is known for a long time as a potent antioxidant, acting either as a primary scavenger of free radicals or in the regeneration of tocopherol. CoQ10 is also involved in oxidative phosphorylation as an electron transporter and is therefore involved in energy homeostasis [17-20]. Data obtained in vitro even suggest its anti-inflammatory potency [21-25]. However, the effect of CoQ10 given orally remains only poorly explored in the context of obesity and diabetes. Among the tissues targeted through oral administration of CoQ10, the liver could be the most relevant since this tissue collects it with quite efficacy, and is thus considered as one of the storage pool of CoQ10 [26,27].

Therefore, we have tested the metabolic effect of CoQ10 supplementation in metabolic alterations induced by combination of HF diet and fructose supplementation in mice, with special highlight on liver consequences.

2. Experimental methods

2.1 Animals and diets

Ten-week-old male C57BL/6J mice (Charles River Laboratories, France) were housed in groups of four mice per cage (eight mice per group) at 22°C with sequential light/dark cycle (lights off 6 pm, lights on 6 am) and were given free access to diet and water. They were fed either the control diet (CT group; AO4, SAFE, Villemoisson-sur-Orge, France), or a HF diet (SAFE, Villemoisson-sur-Orge, France) and given water containing 21% (wt/V) of fructose (Sigma, St Louis, MO, USA- HFF group) or a HF diet supplemented with 1% CoQ10 (Kaneka, Japan) and 21% of fructose in the water (HFFQ group) for 60 days. The CT diet contained the following (g/100 g dry diet): protein 19.3, total
carbohydrate 70.4 (including starch 38, saccharose 3, cellulose 5 and non-digestible carbohydrates 8), lipid 3, vitamin 1.3 and mineral mixture 6. The HF diet contained 72% lipids (corn oil and lard), 28% protein, and <1% carbohydrates as energy content. Food intake, taking into account spillage, was recorded weekly for two months. Water consumption was also recorded weekly to analyse fructose intake. The mean value for the weekly assessment of food, water and energy intake was calculated. All mice experiments were approved by the local committee and the housing conditions were as specified by the Belgian Law of November 14, 1993 on the protection of laboratory animals (agreement n° LA 1230314) in accordance with the declaration of Helsinki.

2.2 Oral glucose tolerance test

An oral glucose tolerance test was performed 7 weeks after the beginning of the feeding period [7,28,29]. Six-hour-fasted mice received an oral load of glucose (Fluka, Buchs, Switzerland) of 3 g/kg body wt with a 660 g/l glucose solution. Different parameters related to glucose homeostasis have been measured. Blood glucose was determined with a glucose meter (Roche Diagnostics Belgium, Vilvoorde, Belgium) on 3.5µl of blood was collected from the tip of the tail vein, 30 min before and 0, 15, 30, 60, 90 and 120 min following oral glucose administration. Plasma insulin was measured on 5µl of plasma collected from tail blood at 0 and 15 min using an ELISA kit (Mercodia, Upssala, Sweden). The insulin-resistance index was obtained by multiplication of the area under the curve of glucose between 0 and 15 min after glucose administration and the area under the curve of insulin between 0 and 15 min after glucose administration; its unit is mM*pM*min\(^{-2}\) [8,30-32]. The area under the curve was calculated from basal glycemia
up to 120 minutes after the glucose administration, with no correction of the area by the basal value.

2.3 Blood samples
At the end of the experiments, 6-hour-fasted mice were anaesthetized by intra-peritoneal injection of ketamine/xylazine (Anesketin, Eurovet, Bladel, the Netherlands; Rompun, Bayer Belgium, Sint-Truiden, Belgium) 100 and 10 mg/kg, respectively. Cava vein blood samples were collected in EDTA tubes, and plasma was stored at -80°C. Cytokines (Tumor necrosis factor α, TNFα) were determined in 25 µl of plasma using a Multiplex kit (Bio-Rad, Nazareth, Belgium) and measured by using Luminex technology (Bio-Plex System™, Bio-Rad) according to the manufacturer’s instructions.

2.4 Tissue samples
Fat pads (visceral, epididymal and subcutaneous), heart and vastus lateralis muscle were removed, immersed in liquid nitrogen and stored at -80°C for further mRNA and/or lipids analysis. Liver was excised: most of it was immediately clamped in liquid N₂ and kept at -80°C for lipids and mRNA analysis; only a fraction of the main liver lobe was fixed-frozen in isopentane (Lab-Scan, Dublin, Ireland) and kept at -80°C for histological analysis. Liver and fat tissues were weighed.

2.5 Histological analysis
For the detection of inflammation and the determination of integrity of tissue, frozen sections were sliced and stained with hematoxylin-eosin, HE. Other sections were stained with diaminobenzidine, DAB (Sigma), in order to detect endogenous peroxidase.

2.6 Tissues analyses

Triglycerides (TG), phospholipids (PL) and cholesterol (CHO) were measured in the liver tissue after an extraction with chloroform-methanol (Lab-Scan) according to Folch et al [33]. Tissue lysate was prepared in phosphate buffer by using Ultra-Turrax (IKA, T10 basic, Boutersem, Belgique), until complete tissue lysis. Lipids were extracted by mixing 125 µl lysates with 1 ml of chloroform: methanol (2:1). Chloroform phase was evaporated under nitrogen flux, and the dried residue was solubilized in 100 µl of isopropanol (Lab-Scan). Liver PL (Wako, Brussels, Belgium), TG and CHO (Elitech diagnostics, Brussels, Belgium) concentrations were measured using kits coupling enzymatic reaction and spectrophotometric detection of reaction end-products.

Lipid peroxidation was evaluated by measuring thiobarbituric acid reactive substances, TBARS. Tissue lysate was prepared in saline by using Ultra-Turrax (IKA, T10 basic, Boutersem, Belgique), until complete tissue lysis. Aldehydes contained in tissue lysate reacted with thiobarbiuric acid (Fluka) forming an aldehyde-thiobarbituric acid complex, which can be spectrophotometrically detected [34].

Protein carbonyls were measured spectrophotometrically using 2,4-dinitrophenylhydrazine (Aldrich, St Louis, MO, USA), which has an absorbance maxima at 370 nm and a molar extinction coefficient of 22 000 M$^{-1}$ cm$^{-1}$ [35]. Briefly, liver
homogenate was first centrifuged to remove nucleus and cellular debris, and then incubated with streptomycin sulfate (Sigma) to remove nucleic acid in excess. It was then derivatized with 2,4-dinitrophenylhydrazine and proteins were precipitated with trichloroacetic acid (20% followed by 10%; Riedel-de Haën, Seelze, Germany). Pellet was finally washed several times before being suspended in guanidine HCl (Sigma). The carbonyl content in each sample was finally measured spectrophotometrically at 360 nm. To relate carbonyl content to the amount of extracted protein in each sample, the protein content was subsequently measured using Bradford’s method (Bio-Rad) [36].

Phosphorylated form of insulin receptor was quantified in liver extracts using Luminex technology. Liver tissue were homogenized in lysis buffer (50mM Tris, 1% NP40, 5mM EDTA, 250mM NaCl, 50mM NaF, 1mM Na$_3$VO$_4$, proteases inhibitors cocktail (Roche Diagnostics Belgium, Vilvoorde). After 15 min on ice and centrifugation (13 000 g, 10 min, 4°C), supernatants were snap frozen and aliquots were stored at - 80°C. Protein content of supernatants was determined using the Bradford method [36]. The assay was performed by using a Multiplex kit (Akt pathway phospho7plex, BioSource, Nivelles, Belgium) through Luminex technology (Bio-Plex, Bio-Rad) according to the manufacturer’s instructions.

The CoQ9 and CoQ10 concentrations in liver homogenates were measured using HPLC with electrochemical detection and internal standardization modified according to a previously published method for CoQ10 analysis in blood cells [37]. As an internal standard 87 pmol of diethoxy-ubiquinone-10 (kindly provided by B. Janetzky, Technical
University of Dresden, Germany) in 50 µl ethanol were added to a sample of 1 mg tissue homogenate in 100µl saline. The cells were disintegrated by adding cold methanol, extracted with hexane (Riedel-de Haën), and evaporated under a stream of argon. The dry residue was re-dissolved in 50 µl ethanol (Merck, Darmstadt, Germany) and injected into the HPLC system.

2.7 Real-time quantitative PCR

Total RNA was isolated from subcutaneous adipose tissue and liver using TriPure isolation reagent kit (Roche Diagnostics Belgium, Vilvoorde). cDNA was prepared by reverse transcription of 1 µg total RNA using the Kit Reverse transcription System (Promega, Leiden, The Netherlands). Real-time polymerase chain reactions (PCR) were performed with the StepOnePlus real time PCR system and software (Applied Biosystems, Den Ijssel, The Netherlands) using SYBR-Green (Applied Biosystems) for detection. Ribosomal protein L19 (RPL19) RNA was chosen as housekeeping gene. The targeted mouse genes, detailed in table 1, are the following: fatty acid synthase (FAS), NADPH oxidase, cyclooxygenase-2 (COX2), TNFα, C reactive protein (CRP), six-transmembrane protein of prostate 2 (STAMP2), Interleukine-6 (IL6), diacylglycerol O-acyltransferase 2 (DGAT2), camitine palmitoyltransferase 1α (CPT1α), RPL19 and CD68. All tissues were run in duplicate in a single 96-well reaction plate and data were analysed according to the $2^{-\Delta CT}$ method [7]. The identity and purity of the amplified product was checked through analysis of the melting curve carried out at the end of amplification.
Inflammatory score is the sum of NADPH oxidase, COX2, STAMP2, CRP, IL6 and TNFα hepatic mRNA level.

2.8 Statistical analysis

Results are presented as Mean ± SEM. Statistical significance of difference between groups was assessed by one-way ANOVA followed by post hoc Tukey’s multiple comparison tests. Correlations between parameters were assessed by Pearson’s correlation (GraphPad Prism Software, San Diego, CA, USA; www.graphpad.com). Data with different superscript letters are significantly different \( (P<0.05) \) according to the post hoc ANOVA statistical analysis.

3. Results

3.1 Evolution of body weight and metabolic disturbances

Mice fed on HF diet and fructose supplementation gained more weight than the control mice, and CoQ10 supplementation did not modify body weight evolution (figure 1B). After 7 weeks of treatment all mice slightly lost weight following the oral glucose tolerance test. Body weight gain (figure 1A) increases significantly upon HF diet and fructose supplementation, with no modification following CoQ10 supplementation. This increase is reflected through the increase in fat mass and in particular visceral and epididymal fat mass (figure 2 A, B, C). The energy consumption, calculated upon fructose supplementation in the water and diet energy content during the whole duration
of the experiment, is largely increased in both HFF and HFFQ groups in comparison to CT group (figure 1B). Energetic efficiency is the ratio between the body weight gain (g) and the energy intake (kcal) of each mouse. In our study, HF diet and fructose supplementation did not change this parameter but CoQ10 supplementation tends to increase energetic efficiency (figure 1C). Table 2 shows that there is no increase in liver weight upon treatments and HFF mice even show a tendency to lessen relative liver weight (% body weight); this tendency becoming significant in HFFQ mice.

3.2 Coenzyme Q10 enrichment in the liver tissue

Mice are known to synthesize both CoQ9 and CoQ10, which differs one from each other by the length of their isoprenoid side chain. Liver CoQ9 and CoQ10 contents of CT mice are different, with 2.56 pmol/mg of CoQ10 and 70.01 pmol/mg of CoQ9. Liver CoQ9 content in HFF and HFFQ groups and liver CoQ10 content in HFF group are not modified as compared to controls. However CoQ10 supplementation increases by more than 40 times the liver CoQ10 content in HFFQ versus HFF and CT group (figure 3 A, B).

3.3 Lipid homeostasis

The histological analysis of the liver tissue reveals the presence of microvesicular lipid droplets in all groups but macrovesicular lipid droplets accumulate preferentially in HFF and HFFQ groups, signing changes in lipid storage in HF and fructose supplemented
mice (figure 4). The TG, CHO and PL accumulation in the liver tissue was not significantly modified versus CT diet (table 2). However animals supplemented with CoQ10 show a tendency of increased liver TG. Liver weight (table 2), expressed in g, is significantly increased following HF diet and fructose supplementation while it shows a tendency to decrease when expressed in % of body weight, signing that the extent of changes in total body weight largely exceeded the modification in liver weight upon treatment. The addition of CoQ10 lessens the increase in liver weight (expressed in g) and significantly decreases the relative liver weight (expressed in % of body weight). Serum TG, non-esterified fatty acid, and alanine amino transferase and aspartate amino transferase activities were not modified by dietary treatment (data not shown). The expression of the genes involved in lipogenesis (FAS), in fatty acid esterification (DGAT2) and in transport of long chain fatty acids across the mitochondrial membrane, where they can be oxidized (CPT1α) was assessed by the measurement of mRNA content. HFF treatment increases mRNA level of DGAT2 and CPT1α, with no effect on FAS mRNA (table2). However, the addition of CoQ10 blunted the HFF effect on CPT1α.

3.4 Glucose homeostasis

HFF treatment induced glucose intolerance and insulin resistance, as shown by the higher area under the curve and insulin resistance index (figure 5 C, D, E). In both HFF and HFFQ groups, fasting glycemia showed a tendency to increase (figure 4 B) and fasting insulinemia a significant increase as compared to controls (figure 5 A). This latter effect was even higher in CoQ10 treated animals. Insulin receptor phosphorylation on tyrosines
sites 1162 and 1163 is the limiting step of the activation of the insulin receptor. Similar insulin receptor phosphorylation level, as seen between the three groups, signs no difference in the activation rate of insulin receptor (Figure 5 F). However, as HFF and HFFQ fed mice show a higher fasting insulinemia compared to CT mice (figure 5 A), it might reflect a lower response to insulin in HFF and HFFQ fed mice.

3.5 Assessment of hepatic markers of oxidative and inflammatory stresses

HFF treatment significantly increases NADPH oxidase mRNA content in the liver tissue as compared to CT group, while CoQ10 reduces this alteration (figure 6 A). The histological analysis of peroxidase positive cells – signing the total immune cells- in the liver tissue reveals an increase in their number in both HFF and HFFQ groups. No significant modification of CD68 mRNA, reflecting the presence of monocytes and macrophages, occurred in the treated groups (figure 6 G). HFF treatment increases by several fold the inflammatory protein precursors, STAMP2 and CRP, respectively by 6 and 3 fold (figure 6 C, D). COX2, IL6 and TNFα mRNA show no significant modification upon treatment but a similar profile: an increase by HFF and a decrease in HFFQ (figure 6 B, E, F). An inflammatory score was calculated, by summing the mRNA level of all COX2, STAMP2, CRP, IL6 and TNFα hepatic mRNA level. This inflammatory score is significantly increased upon HFF treatment and tend to be blunted upon CoQ10 supplementation (Figure 6 I). Serum TNFα evolution upon treatment is similar to the evolution of TNFα mRNA in the liver tissue upon same treatments (figure 6 F, H). TBARS have been measured in the liver, muscle, adipose tissues and in the
heart (table 3 A): HFF treatment leads to a decrease in peroxidation end products in all tissues, except in the subcutaneous adipose tissue; this drop being significant in liver and visceral white adipose tissue. CoQ10 per se did not modify lipid peroxides level versus the HFF group. Liver carbonylated proteins were modified neither by HFF treatment nor upon CoQ10 supplementation (table 3 B). A clear correlation (figure 7) could be done between markers of inflammatory stress – CRP or STAMP2 mRNA expression- and oxidative stress – NADPH oxidase mRNA expression- (figure 7 B,C,E) suggesting an association between inflammation and oxidative stress in a model of diet induced obesity. Moreover, correlations between the markers inflammation or oxidative stress (CRP, STAMP2 and NADPH oxidase mRNA expression) and CPT1α mRNA expression could also be done (figure 7 A,D,F).

4 Discussion

The aim of the study was to assess the effect of CoQ10 oral administration on the metabolic disturbances occurring in a model of obesity in mice, by focusing on potential effect that occur independently on the well known protective effect of CoQ10 against lipid peroxidation.

The first part of the discussion will focus on the model used in our study. We know that HF feeding is responsible for the development of obesity and leads to insulin resistance within a few weeks in mice [8]. Here we confirm that the HF diet-induced obesity and glucose intolerance are independent of lipid peroxidation, since the level of tissue lipid peroxides are paradoxically strongly blunted due to a high vitamin E content of the HF
diet [32]. On the other hand, fructose supplementation has been extensively studied in rodents, especially in rats, and has been shown to promote insulin resistance and inflammation [14,15]. Few mice studies suggest that the metabolic response towards high fructose diets provides discrepant results concerning the effect on body weight, glucose and lipid homeostasis [38-40]. Messier et al [39] have shown that the combination of HF diet and fructose supplementation in mice leads to increased weight gain and impairments in blood glucose regulation, but this combination model has not been extensively studied. In our study, we confirm the huge accumulation of fat mass and the increase in body weight when high fat is supplemented with fructose.

Concerning the liver, we have observed that HF plus fructose supplementation in mice changes several, but not all the enzymes involved in fatty acid storage. We did not found any inducement of the expression of key enzymes involved in lipogenesis since HFF treatment did not increased FAS. However, the observed increase in the expression of DGAT2 - an enzyme which catalyses the final step of TG synthesis- could also be implicated in hepatic lipid accumulation, together with the fact that fructose is an excellent lipogenic substrate [12,41]. HF plus fructose diet induces a shift from microvesicular towards macrovesicular lipid storage as analysed by histology. However, the content in TG, CHO and PL was only slightly and not significantly increased. Therefore, it seems that steatosis in this nutritional context is more related to qualitative changes of lipid droplet than to drastic changes in lipid storage. The lack of massive lipid accumulation might be explained by the fact that the sampling was performed at a late post-absorptive state (six hours after food removal). Moreover, the increase in mRNA
expression of CPT1α could drive an increased oxidation of fatty acids, thus counteracting a huge increase in lipid accumulation despite the high content of fat in the diet. HFF mice also present an altered glucose response, already generated through HF diet given independently on fructose administration [8]. Interestingly, this HFF models also drives inflammation in the liver tissue as shown by the higher COX2, CRP, IL6, TNFα and STAMP2 mRNA levels. HFF treatment also provokes an increased expression of NADPH oxidase, considered as an early event associating oxidative reactive species production and inflammatory stress [10,42]. Despite this fact and as previously demonstrated, liver lipid peroxide content remains very low in the liver tissue[32].

Several data recently obtained in human have tried to correlate the markers of lipid peroxidation with metabolic alterations linked to obesity. The oxidative stress, assessed i.e. by lipid peroxides measurement in the blood, is increased in patients exhibiting a metabolic syndrome [43]. By analysing several markers of oxidative stress, Rytter et al have shown that only 8-iso-PGF2α is positively correlated with HbA1c and blood glucose in diabetic subjects [44]. Our data in animal clearly show that lipid peroxidation is not a prerequisite to observe the metabolic alterations linked to high fat diet induced obesity.

Curiously, hepatic CPT1α mRNA increases upon HFF treatment. Besides its role in the transport of long chain fatty acids across the mitochondrial membranes, CPT1α activity has recently been associated with food intake in rats. In the brain, an inhibition of CPT1α activity could lead to the accumulation of fatty acids and this accumulation can be integrated as a signal of nutrient abundance finally leading to a decreased food intake.
Furthermore, liver CPT1α expression has been shown to be increased following HF diet [46], exercise training or diet restriction [47]. Therefore, we hypothesised that CPT1α could be seen as a marker of global catabolic state under metabolic stress condition. In our study, a clear correlation (figure 7) could be found between markers of inflammatory stress and oxidative stress suggesting that all these metabolic features are clearly present and linked one to each other in this model of dietary induced obesity.

We have used the model HF diet supplemented with fructose to assess the potential interest of CoQ10 supplementation. CoQ10 is an important cofactor of the electron transport chain in mitochondrial respiration, being involved in energy homeostasis [17,19,48,49]. Furthermore it is also a cofactor of mitochondrial uncoupling proteins, which activation leads to a reduction of mitochondrial-free radical generation [50,51]. In our study, beside a described low tissue uptake [26,27], we found a 40 times increase of CoQ10 level in the liver tissue.

However, in our study, we did not find any modification of liver lipid accumulation following CoQ10 supplementation. Another antioxidant such as vitamin E, has been shown to lessen the hepatic fibrosis occurring in a model of mice mimicking the steatohepatitis (methionine and choline deficient diet) [52] We can therefore propose that the beneficial effect of antioxidant might be dependent on the nature of the hepatic alteration occurring upon nutritional manipulation, and would be more efficient to counteract the pathogenic process leading to steatohepatitis than counteracting steatosis per se.

Some studies suggest that CoQ10 may exhibit anti-inflammatory properties, but most of those data have been obtained in vitro. Doring et al.[23] and Schmelzer et al. [24]
analysed \textit{in silico} the CoQ10 effect on in vitro human and murine macrophages and found upregulation of 17 genes functionally connected by signalling pathways of G-protein coupled receptors, JAK/STAT, integrin and β-arrestin, and five of this genes code for protein involved in inflammation (IL5, thrombin, vitronectin, vitronectin receptor and CRP). In vitro macrophages cells lines (RAW and THP-1) pretreated with CoQ10 show reduced TNF\(\alpha\) release (RAW)[22] and reduced TNF\(\alpha\), MIP-1\(\alpha\) and RANTES (THP-1)[25] after LPS stimulation. Finally, Fuller et al. observed that CoQ10 is able to suppress UV radiation or IL-1-induced inflammatory response in dermal fibroblasts. Here we provide for the first time in vivo evidence that an accumulation of CoQ10 in the liver tissue, allows to blunt NADPH oxidase expression and inflammatory stress, independently on any effect on lipid peroxidation, in a model of diet induced obesity. This is rather interesting, since it is in accordance with the data obtained in vivo in other models, and that focused on systemic inflammation. However, CoQ10 supplementation does not blunt the increase of total tissue fixed or recruited immune cells following HFF treatment as assessed by histological analysis of peroxidase positive cells. Another in vivo study shows that in a model of hypertensive rats developing metabolic syndrome following HF diet, CoQ10 reduce serum CRP level, thereby decreasing the inflammatory stress [53]. In another study, anti-inflammatory properties of CoQ10 on serum CRP levels of baboons have also been observed, but only when combined with vitamin E. This modification of serum CRP level was associated with an increase blood total antioxidant status [54]. Recently, Carmona et al. [16] showed that i.p. injection of CoQ10 modulates blood lipid profiles and the expression of pro-inflammatory cytokine in the adipose tissue. Those different in vitro and in vivo studies seems to show a potential role of
CoQ10 in inflammation, but its potential anti-inflammatory effect is still not clearly associated with any improvements of metabolic disorders. While others antioxidants have clearly been associated with improvements of metabolic disorders e.g. berries rich in anthocyanin induce a decrease in adipose tissue inflammation which is associated with a reduction of insulin resistance[55].

We propose, in view of our study, that CoQ10, when given orally, is able to target the liver tissue, and to lessen inflammatory stress associated with obesity in mice in this tissue, independent on any action on lipid peroxidation. However, this effect was not sufficient to counteract fat mass development and other metabolic alterations occurring upon obesity (steatosis, altered glucose response). The hepatic effect of CoQ10 could be interesting to study in the context of non alcoholic steatohepatitis that clearly associate fat accumulation and inflammation in the liver tissue.

Conflict of interest statement

The authors have no conflict of interest.

Acknowledgments

This work was supported by Kaneka Inc. and by the Région Wallonne (WalNut 20 Project). P.D. Cani is a Research Associate from the FNRS Belgium.

Reference list


Figures

Figure 1: Body weight gain and consumption. Body weight gain in CT, HFF and HFFQ mice after an 8-week period of feeding (A). Evolution of body weight during the 8-week period of feeding (B). Energy consumption per cage of four mice, calculated upon fructose supplementation and diet energy content, during the 8-week period of feeding (C). Energetic efficiency in CT, HFF and HFFQ mice, calculated upon body weight gain and energy consumption (D). Data are mean ± SEM. Data with different superscript letters are significantly different p<0.05, according to the post hoc ANOVA statistical analysis (A,B,D). Data are mean of 2 cages with 4 mice each (n=2, B). CT (n=7) Control diet, HFF (n=8) High-fat diet and fructose, HFFQ (n=8) High-fat diet, fructose and coenzyme Q10

Figure 2: Effect of different diet on adipose tissue weight: visceral (A), epididymal (B) and subcutaneous (C) in CT (n=7), HFF (n=8) and HFFQ (n=8) mice after an 8-week period of feeding. Data are mean ± SEM. Data with different superscript letters are significantly different p<0.05, according to the post hoc ANOVA statistical analysis. CT Control diet, HFF High-fat diet and fructose, HFFQ High-fat diet, fructose and coenzyme Q10

Figure 3: Effect of different diet on CoQ content in the liver: CoQ10 (A) and CoQ9 (B) in CT (n=7), HFF (n=8) and HFFQ (n=8) mice after an 8-week period of feeding. Data are mean ± SEM. Data with different superscript letters are significantly different p<0.05,
according to the post hoc ANOVA statistical analysis. CoQ coenzyme Q, CT Control diet, HFF High-fat diet and fructose, HFFQ High-fat diet, fructose and coenzyme Q10

Figure 4: Histological analysis of liver tissue (HE staining) in CT (A), HFF (B) and HFFQ (C) mice. Bar = 50 μm. CT Control diet, HFF High-fat diet and fructose, HFFQ High-fat diet, fructose and coenzyme Q10

Figure 5: Effect of different diet on glucose tolerance in mice A. Fasted plasma insulin (pmo/l) in CT (n=7), HFF (n=8) and HFFQ (n=8) mice after a 7-week period of feeding. B. Fasted plasma glucose (mmol/l) in the same groups; p=0.05 C. Plasma glucose following an oral glucose load (3 g/kg) in CT (closed squares), HFF (closed circles) and HFFQ (open squares). D. Area under the curve of glycemia (AUC, mmol/l*min) in the same groups. E The insulin-resistance index –AUC glucose 0-15 min X AUC insulin 0-15 min- in the same groups [μmol*15min]². F. The phosphorylation of insulin receptor in the same groups. Data are mean ± SEM. Data with different superscript letters are significantly different p<0.05, according to the post hoc ANOVA statistical analysis. AUC, area under the curve, IR insulin receptor, CT Control diet, HFF High-fat diet and fructose, HFFQ High-fat diet, fructose and coenzyme Q10

Figure 6: Effect of different diet on inflammatory and oxidative stress markers in CT (n=7), HFF (n=8) and HFFQ (n=8) mice after an 8-week period of feeding A. Liver NADPH oxidase mRNA level (relative expression). B. Liver COX2 mRNA level
(relative expression). C. Liver STAMP2 mRNA level (relative expression). D. Liver CRP mRNA level (relative expression). E. Liver IL6 mRNA level (relative expression). F. Liver TNFα mRNA level (relative expression). G. Liver CD68 mRNA level (relative expression). H. TNFα level in serum (pg/ml). I. Liver inflammatory score, sum of liver NADPH oxidase, COX2, STAMP2, CRP, TNFα and IL6 mRNA level (relative expression). Data are mean ± SEM. Data with different superscript letters are significantly different p<0.05, according to the post hoc ANOVA statistical analysis.

TNF-α tumor necrosis factor-α, STAMP2 six-transmembrane protein of prostate 2, COX-2 cyclooxygenase-2, IL6 interleukine 6, CRP C reactive protein, CT Control diet, HFF High-fat diet and fructose, HFFQ High-fat diet, fructose and coenzyme Q10

Figure 7: Correlations between liver CRP, STAMP2, CPT1α and NADPH oxidase mRNA. Correlation between: A. liver CRP mRNA and liver CPT1α mRNA, B. liver CRP mRNA and liver STAMP2 mRNA, C. liver CRP mRNA and liver NADPH oxidase mRNA, D. liver STAMP2 mRNA and liver CPT1α mRNA, E. liver STAMP2 mRNA and liver NADPH oxidase mRNA, F. liver CPT1α mRNA and liver NADPH oxidase mRNA. n =23, statistical analysis: Pearson’s r correlations. CRP C reactive protein, STAMP2 six-transmembrane protein of prostate 2, CPT1α carnitine palmitoyltransferase 1α
Tables

Table 1: Primers sequences used for real-time quantitative PCR

TNF-α, tumor necrosis factor-α; RPL19, ribosomal protein L19; STAMP2, six-transmembrane protein of prostate 2; COX-2, cyclooxygenase-2; FAS, fatty acid synthase; IL6, interleukine-6; DGAT-2, diacylglycerol O-acyltransferase 2; CPT1-α, carnitine palmitoyltransferase 1α; CRP, C reactive protein.

Table 2: Liver parameters

Data are mean ± SEM. Data with different superscript letters are significantly different p<0.05, according to the post hoc ANOVA statistical analysis. TG triglycerides, CHO cholesterol, PL phospholipids, FAS fatty acid synthase, DGAT2 diacylglycerol O-acyltransferase 2, CPT1α carnitine palmitoyltransferase 1α, CT Control diet, HFF High-fat diet and fructose, HFFQ High-fat diet, fructose and coenzyme Q10

Table 3: TBARS and carbonylated proteins in tissues.

Data are mean ± SEM (n ≥ 6). Data with different superscript letters are significantly different p<0.05, according to the post hoc ANOVA statistical analysis. CT Control diet, HFF High-fat diet and fructose, HFFQ High-fat diet, fructose and coenzyme Q10, SAT subcutaneous adipose tissue, EAT epididymal adipose tissue, VAT visceral adipose tissue.
Table 1

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNF-α</td>
<td>AAATGGGCTCCCTCTCATCAGTTC</td>
<td>TCTGCTTGGTGGTTTGCTACGAC</td>
</tr>
<tr>
<td>RPL19</td>
<td>GAAGGTCAAGGGGAATGTGTTCA</td>
<td>CTTTGCTTGCTCCTCAGCTTGT</td>
</tr>
<tr>
<td>NADPH oxidase</td>
<td>TTGGGTCAGCAGCTGGCTCTTG</td>
<td>TGGCGGTGTCAGCTGCTATC</td>
</tr>
<tr>
<td>COX-2</td>
<td>TGACCCCCCAAGGCTCAATAT</td>
<td>TGAACCCAGGTCCTCGCTTA</td>
</tr>
<tr>
<td>FAS</td>
<td>TTCCAAGACGAAATGATGTC</td>
<td>AATTGTGGGATCAGGAGGC</td>
</tr>
<tr>
<td>DGAT2</td>
<td>ACTCTGGAGGTTGGCAACCAT</td>
<td>GGGTGGTCAGCTCAGAGGAT</td>
</tr>
<tr>
<td>IL6</td>
<td>TCCTACCCCCAATCTCCTGCTC</td>
<td>TGGATGGTCTTTGTCCTTACCC</td>
</tr>
<tr>
<td>CPT1α</td>
<td>AGACCGTGAGGAACTCAAACCTAT</td>
<td>TGAAGAGTCAGCTCCCAC</td>
</tr>
<tr>
<td>CRP</td>
<td>CCATTTCTACACTGCTGTACGCAC</td>
<td>CCAAAATAATGAGAATGTCCTAGAGTTTC</td>
</tr>
<tr>
<td>STAMP2</td>
<td>TCAATGCAGACAAACCTTGCT</td>
<td>GCATCTAGCTCTGACTGGA</td>
</tr>
<tr>
<td>CD68</td>
<td>CTTCCACGAGGACACAG</td>
<td>AATGATGAGGACAGCAAGAGG</td>
</tr>
</tbody>
</table>
Table 2

<table>
<thead>
<tr>
<th></th>
<th>CT</th>
<th>HFF</th>
<th>HFFQ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver weight (g)</td>
<td>1.06 ± 0.03&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.19 ± 0.03&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1.14 ± 0.03&lt;sup&gt;ab&lt;/sup&gt;</td>
</tr>
<tr>
<td>Liver weight (% body weight)</td>
<td>4.0 ± 0.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3.8 ± 0.1&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>3.5 ± 0.1&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Liver TG (nmol/mg prot)</td>
<td>87.5 ± 7.9</td>
<td>92.9 ± 14.4</td>
<td>114.6 ± 7.7</td>
</tr>
<tr>
<td>Liver CHO (nmol/mg prot)</td>
<td>64.1 ± 4.5</td>
<td>72.5 ± 3.4</td>
<td>75.4 ± 2.8</td>
</tr>
<tr>
<td>Liver PL (nmol/mg prot)</td>
<td>87.8 ± 2.4</td>
<td>91.4 ± 3.3</td>
<td>89.3 ± 3.6</td>
</tr>
<tr>
<td>Liver FAS (relative expression)</td>
<td>1.00 ± 0.13</td>
<td>0.84 ± 0.05</td>
<td>0.99 ± 0.10</td>
</tr>
<tr>
<td>Liver CPT1α (relative expression)</td>
<td>1.00 ± 0.08&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.88 ± 0.38&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1.28 ± 0.11&lt;sup&gt;ab&lt;/sup&gt;</td>
</tr>
<tr>
<td>Liver DGAT2 (relative expression)</td>
<td>1.00 ± 0.04&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.45 ± 0.07&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1.46 ± 0.10&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>
Table 3

<table>
<thead>
<tr>
<th></th>
<th>CT</th>
<th>HFF</th>
<th>HFFQ</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Liver TBARS</strong></td>
<td>13,0 ± 2,2a</td>
<td>4,9 ± 0,3b</td>
<td>5,1 ± 1,4b</td>
</tr>
<tr>
<td><strong>Muscle TBARS</strong></td>
<td>4,8 ± 0,8a</td>
<td>3,1 ± 0,6ab</td>
<td>2,3 ± 0,5b</td>
</tr>
<tr>
<td><strong>SAT TBARS</strong></td>
<td>4,9 ± 1,0</td>
<td>8,7 ± 2,3</td>
<td>7,8 ± 0,9</td>
</tr>
<tr>
<td><strong>EAT TBARS</strong></td>
<td>6,8 ± 2,3</td>
<td>5,5 ± 1,1</td>
<td>5,4 ± 1,2</td>
</tr>
<tr>
<td><strong>VAT TBARS</strong></td>
<td>12,3 ± 2,4a</td>
<td>4,3 ± 0,3b</td>
<td>4,7 ± 1,5b</td>
</tr>
<tr>
<td><strong>Heart TBARS</strong></td>
<td>31,2 ± 5,8</td>
<td>20,4 ± 1,5</td>
<td>19,5 ± 0,9</td>
</tr>
<tr>
<td><strong>(µmol MDA/L homogenate H/10)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>CT</th>
<th>HFF</th>
<th>HFFQ</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Liver carbonylated proteins</strong></td>
<td>1,3 ± 0,1</td>
<td>1,4 ± 0,2</td>
<td>1,1 ± 0,1</td>
</tr>
<tr>
<td><strong>(nmol/mg prot)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 1

- CT
- HFF
- HFFQ

Energetic efficiency (g BW gain/kcal)
Figure 2
Figure 3
Figure 4
Figure

A

![Bar chart showing plasma insulin levels with CT, HFF, and HFFQ groups.](image)

B

![Bar chart showing plasma glucose levels with CT, HFF, and HFFQ groups.](image)

C

![Line graph showing plasma glucose levels over time with CT, HFF, and HFFQ groups.](image)
Figure 5
Figure 6
Figure 7
Graphical Abstract

Glycemia during oral tolerance glucose test (OGTT)

Body weight gain

Inflammatory score (Global hepatic mRNA expression)